Phase 2
๐ Investigational Drug / Biologic
NCT07175051
Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin
๐ University of Illinois Chicago, Sickle Cell Center โ Chicago, Illinois
View Study & Screener โ